Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Page 1
Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study.
Ip JE, Coutu B, Bennett MT, Pandey AS, Stambler BS, Sager P, Chen M, Shardonofsky S, Plat F, Camm AJ. Ip JE, et al. Among authors: plat f. J Am Heart Assoc. 2023 Oct 3;12(19):e028227. doi: 10.1161/JAHA.122.028227. Epub 2023 Sep 27. J Am Heart Assoc. 2023. PMID: 37753718 Free PMC article. Clinical Trial.
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieśliński A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Störset O. Zanchetti A, et al. Among authors: plat f. J Hypertens. 2006 Nov;24(11):2163-8. doi: 10.1097/01.hjh.0000249692.96488.46. J Hypertens. 2006. PMID: 17053536 Clinical Trial.
BACKGROUND: In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary outcome (cardiac morbidity and mortality) did not differ between valsartan and amlodipine-based treatment groups, although systolic blood pressure (SBP) and diastolic blood pre …
BACKGROUND: In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary outcome (cardiac morbidity and morta …
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Weber MA, et al. Among authors: plat f. Lancet. 2004 Jun 19;363(9426):2049-51. doi: 10.1016/S0140-6736(04)16456-8. Lancet. 2004. PMID: 15207957
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on valsartan or amlodipine would have differing effects on cardiovascular endpoints in high risk hypertension. ...
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test whether, for the same achieved blood press …
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Julius S, et al. Among authors: plat f. Lancet. 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9. Lancet. 2004. PMID: 15207952 Clinical Trial.
BACKGROUND: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high card …
BACKGROUND: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the sa …